search
Back to results

Study of Lumbar Discectomy With Annular Closure

Primary Purpose

Lumbar Disc Herniation

Status
Active
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Annular closure device
Sponsored by
Intrinsic Therapeutics
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Lumbar Disc Herniation

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Age 18 to 75 years old and skeletally mature (male or female)
  2. Subjects with posterior or posterolateral disc herniations at one level between L4 and S1 with radiographic confirmation of neural compression using MRI. [Note: Intraoperatively, only patients with an anular defect (post discectomy) between 4mm and 6mm tall and 6mm and 10mm wide shall qualify.]
  3. At least six (6) weeks of failed, conservative treatment prior to surgery, including physical therapy, use of anti-inflammatory medications at maximum specified dosage and/or administration of epidural/facet injections.;
  4. Minimum posterior disc height of 5mm at the index level.
  5. Radiculopathy (with or without back pain) with a positive Straight Leg Raise (0 - 60 degrees)
  6. Oswestry Questionnaire score of at least 40/100 at baseline.
  7. VAS leg pain (one or both legs) of at least 40/100 at baseline.
  8. Psychosocially, mentally and physically able to fully comply with the clinical protocol and willing to adhere to follow-up schedule and requirements.

Exclusion Criteria:

  1. Spondylolisthesis Grade II or higher (25% slip or greater).
  2. Subject requires spinal surgery other than a discectomy (with or without laminotomy) to treat leg/back pain (scar tissue and osteophyte removal is allowed).
  3. Subject has back or non-radicular leg pain of unknown etiology.
  4. Prior surgery at the index lumbar vertebral level
  5. Subject requiring a spine DEXA (i.e., patients with SCORE of ≥ 6) with a T Score less than -2.0 at the index level. For patients with a herniation at L5/S1, the average T score of L1-L4 shall be used.
  6. Subject has clinically compromised vertebral bodies in the lumbosacral region due to any traumatic, neoplastic, metabolic, or infectious pathology.
  7. Subject has sustained pathologic fractures of the vertebra or multiple fractures of the vertebra or hip
  8. Subject has scoliosis of greater than ten (10) degrees (both angular and rotational).
  9. Any metabolic bone disease.
  10. Subject has an active infection either systemic or local.
  11. Subject has cauda equina syndrome or neurogenic bowel/bladder dysfunction.
  12. Subject has severe arterial insufficiency of the legs or other peripheral vascular disease. (Screening on physical examination for patients with diminution or absence of dorsalis pedis or posterior tibialis pulses. If diminished or absent by palpation, then an arterial ultrasound is required with vascular plethysmography. If the absolute arterial pressure is below 50mm of Hg at the calf or ankle level, then the patient is to be excluded.)
  13. Subject has significant peripheral neuropathy, defined as a subject with Type I or Type II diabetes or similar systemic metabolic condition causing decreased sensation in a stocking-like or non-radicular and non-dermatomal distribution in the lower extremities.
  14. Subject has insulin-dependent diabetes mellitus.
  15. Subject is morbidly obese (defined as a body mass index >40, or weighs more than 100 lbs over ideal body weight).
  16. Subject has been diagnosed with active hepatitis, AIDS, or HIV.
  17. Subject has been diagnosed with rheumatoid arthritis or other autoimmune disease.
  18. Subject has a known allergy to titanium, polyethylene or polyester materials.
  19. Any subject that cannot have a baseline MRI taken.
  20. Subject is pregnant or interested in becoming pregnant in the next 2 years.
  21. Subject has active tuberculosis or has had tuberculosis in the past three (3) years.
  22. Subject has a history of active malignancy: A subject with a history of any invasive malignancy (except non-melanoma skin cancer), unless he/she has been treated with curative intent and there have been no signs or symptoms of the malignancy for at least two (2) years.
  23. Subject is immunologically suppressed, received steroids >1 month over the past year.
  24. Currently taking anticoagulants, other than aspirin, unless the patient can be taken off the anticoagulant for surgery.
  25. Subject has a current chemical/alcohol dependency or significant psychosocial disturbance.
  26. Subject has a life expectancy of less than three (3) years.
  27. Subject is currently involved in active spinal litigation.
  28. Subject is currently involved in another investigational study.
  29. Subject is incarcerated.
  30. Any contraindication for MRI (e.g. claustrophobia, contrast allergy).

Sites / Locations

  • UC San Diego Health System
  • Baptist - Lyerly Neurosurgery
  • North Shore University Health System
  • Indiana Spine Group
  • Orthopaedic Institute of Western Kentucky
  • Louisiana Spine Institute
  • Salt Lake Orthopaedic Clinic

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

Annular closure device

Arm Description

Single arm study; all patients treated with an annular closure device

Outcomes

Primary Outcome Measures

Blood loss
Amount of blood loss measured in ml
Procedure time
Length of surgery, measured in minutes
Hospital stay
Length of the hospital stay measured in days between hospital admission and hospital discharge
Discharge status
Evaluation of improvement in motor and sensory neurologic status
Leg pain severity (0-100 VAS score)
Change from baseline of Visual Analogue Scale score (values between 0-100), with lower values representing better outcome
Back pain severity (0-100 VAS score)
Change from baseline of Visual Analogue Scale score (values between 0-100), with lower values representing better outcome
ODI
Change from baseline in Oswestry Disability Index. The ODI is scored on a scale from 0% to 100%, with higher scores indicating higher levels of disability
EQ-5D
Change from baseline in EQ-5D. The EuroQol (EQ-5D) is a generic utility measure used to characterize current health states. The subject-reported questionnaire consists of 5 domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each of which can take one of three responses. Possible responses include three levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension
Satisfaction with surgery procedure
Patient satisfaction with surgery and treatment assessed utilizing questionnaire with Composite questionnaire with 2 questions will be administered; 1.) Indicate degree of satisfaction with the outcome and 2.) likelihood of recommending the procedure to others
Neurological assessment
Change from baseline in sensory (sensation response at dermatomal levels) reflex, (knee jerk, ankle jerk, response measured as "normal", "increased", "absent" and "decreased") and muscle strength measured 0-5 with "0" representing no evidence of motor strength and "5" representing full resistance
Adverse events
Change of health status with occurrence of adverse event, reported by seriousness and relationship to the device or procedure
Hospital readmission occurrence
Change from baseline in incidence of re-admissions to hospital, post treatment
Symptomatic reherniation incidence
Change from baseline in incidence of post-operative recurrent herniation at the index level. Recurrent herniation may be confirmed surgically, or radiographically as determined by an independent review
Reoperation incidence
Change from baseline in incidence of post-operative reoperation at the index level
Return to work assessment
Change from baseline in work status (ability to return to work, with or without reported restrictions)
Opioid consumption
Change from baseline for all opioid based medications (routes of administration (oral, IV, transdermal), dosing (mg/ml/tablet), duration (days)).

Secondary Outcome Measures

Full Information

First Posted
June 6, 2019
Last Updated
September 27, 2023
Sponsor
Intrinsic Therapeutics
search

1. Study Identification

Unique Protocol Identification Number
NCT03986580
Brief Title
Study of Lumbar Discectomy With Annular Closure
Official Title
Prospective Evaluation Of Lumbar Discectomy With Additional Implantation Of An Annular Closure Device In Patients With Large Postsurgical Annular Defects For Prevention Of Lumbar Disc Reherniation
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
May 1, 2020 (Actual)
Primary Completion Date
June 2024 (Anticipated)
Study Completion Date
December 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Intrinsic Therapeutics

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this prospective, single-arm, multicenter study is to assess an annular closure device when used as an adjunct to a primary lumbar limited discectomy, to limited discectomy alone.
Detailed Description
This single-arm case series will enroll 75 patients at select US (approximately 8-10) sites. Patients that are scheduled for a single-level L4-S1 discectomy and who meet the pre-operative eligibility criteria will be considered for study participation. Patients that meet all intraoperative criteria will be enrolled into the study and treated with lumbar discectomy and additional annular closure device implantation. All enrolled subjects will be followed for at least 12 months.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lumbar Disc Herniation

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
55 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Annular closure device
Arm Type
Other
Arm Description
Single arm study; all patients treated with an annular closure device
Intervention Type
Device
Intervention Name(s)
Annular closure device
Intervention Description
Annular closure, following limited discectomy procedure at a single LS level between L4 and S1
Primary Outcome Measure Information:
Title
Blood loss
Description
Amount of blood loss measured in ml
Time Frame
Intra-operative
Title
Procedure time
Description
Length of surgery, measured in minutes
Time Frame
Intra-operative
Title
Hospital stay
Description
Length of the hospital stay measured in days between hospital admission and hospital discharge
Time Frame
Post-procedure hospital discharge day (in average between 1 and 3 days post surgery)
Title
Discharge status
Description
Evaluation of improvement in motor and sensory neurologic status
Time Frame
Post-procedure hospital discharge day (in average between 1 and 3 days post surgery)
Title
Leg pain severity (0-100 VAS score)
Description
Change from baseline of Visual Analogue Scale score (values between 0-100), with lower values representing better outcome
Time Frame
Baseline, 4 Weeks, 3 Months, 1 year
Title
Back pain severity (0-100 VAS score)
Description
Change from baseline of Visual Analogue Scale score (values between 0-100), with lower values representing better outcome
Time Frame
Baseline, 4 Weeks, 3 Months, 1 year
Title
ODI
Description
Change from baseline in Oswestry Disability Index. The ODI is scored on a scale from 0% to 100%, with higher scores indicating higher levels of disability
Time Frame
Baseline, 4 Weeks, 3 Months, 1 year
Title
EQ-5D
Description
Change from baseline in EQ-5D. The EuroQol (EQ-5D) is a generic utility measure used to characterize current health states. The subject-reported questionnaire consists of 5 domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each of which can take one of three responses. Possible responses include three levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension
Time Frame
Baseline, 4 Weeks, 3 Months, 1 year
Title
Satisfaction with surgery procedure
Description
Patient satisfaction with surgery and treatment assessed utilizing questionnaire with Composite questionnaire with 2 questions will be administered; 1.) Indicate degree of satisfaction with the outcome and 2.) likelihood of recommending the procedure to others
Time Frame
1 year
Title
Neurological assessment
Description
Change from baseline in sensory (sensation response at dermatomal levels) reflex, (knee jerk, ankle jerk, response measured as "normal", "increased", "absent" and "decreased") and muscle strength measured 0-5 with "0" representing no evidence of motor strength and "5" representing full resistance
Time Frame
Baseline, 4 Weeks, 3 Months, 1 year
Title
Adverse events
Description
Change of health status with occurrence of adverse event, reported by seriousness and relationship to the device or procedure
Time Frame
Baseline, Intra-operative, 4 Weeks, 3 Months, 1 year
Title
Hospital readmission occurrence
Description
Change from baseline in incidence of re-admissions to hospital, post treatment
Time Frame
Post-procedure hospital discharge day (in average between 1 and 3 days post surgery), 4 Weeks, 3 Months, 1 year
Title
Symptomatic reherniation incidence
Description
Change from baseline in incidence of post-operative recurrent herniation at the index level. Recurrent herniation may be confirmed surgically, or radiographically as determined by an independent review
Time Frame
Post-procedure hospital discharge day (in average between 1 and 3 days post surgery), 4 Weeks, 3 Months, 1 year
Title
Reoperation incidence
Description
Change from baseline in incidence of post-operative reoperation at the index level
Time Frame
Post-procedure hospital discharge day (in average between 1 and 3 days post surgery), 4 Weeks, 3 Months, 1 year
Title
Return to work assessment
Description
Change from baseline in work status (ability to return to work, with or without reported restrictions)
Time Frame
4 Weeks, 3 Months, 1 year
Title
Opioid consumption
Description
Change from baseline for all opioid based medications (routes of administration (oral, IV, transdermal), dosing (mg/ml/tablet), duration (days)).
Time Frame
Baseline, Intra-operative, Post-procedure hospital discharge day (in average between 1 and 3 days post surgery), 4 Weeks, 3 Months, 1 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 18 to 75 years old and skeletally mature (male or female) Subjects with posterior or posterolateral disc herniations at one level between L4 and S1 with radiographic confirmation of neural compression using MRI. [Note: Intraoperatively, only patients with an anular defect (post discectomy) between 4mm and 6mm tall and 6mm and 10mm wide shall qualify.] At least six (6) weeks of failed, conservative treatment prior to surgery, including physical therapy, use of anti-inflammatory medications at maximum specified dosage and/or administration of epidural/facet injections.; Minimum posterior disc height of 5mm at the index level. Radiculopathy (with or without back pain) with a positive Straight Leg Raise (0 - 60 degrees) Oswestry Questionnaire score of at least 40/100 at baseline. VAS leg pain (one or both legs) of at least 40/100 at baseline. Psychosocially, mentally and physically able to fully comply with the clinical protocol and willing to adhere to follow-up schedule and requirements. Exclusion Criteria: Spondylolisthesis Grade II or higher (25% slip or greater). Subject requires spinal surgery other than a discectomy (with or without laminotomy) to treat leg/back pain (scar tissue and osteophyte removal is allowed). Subject has back or non-radicular leg pain of unknown etiology. Prior surgery at the index lumbar vertebral level Subject requiring a spine DEXA (i.e., patients with SCORE of ≥ 6) with a T Score less than -2.0 at the index level. For patients with a herniation at L5/S1, the average T score of L1-L4 shall be used. Subject has clinically compromised vertebral bodies in the lumbosacral region due to any traumatic, neoplastic, metabolic, or infectious pathology. Subject has sustained pathologic fractures of the vertebra or multiple fractures of the vertebra or hip Subject has scoliosis of greater than ten (10) degrees (both angular and rotational). Any metabolic bone disease. Subject has an active infection either systemic or local. Subject has cauda equina syndrome or neurogenic bowel/bladder dysfunction. Subject has severe arterial insufficiency of the legs or other peripheral vascular disease. (Screening on physical examination for patients with diminution or absence of dorsalis pedis or posterior tibialis pulses. If diminished or absent by palpation, then an arterial ultrasound is required with vascular plethysmography. If the absolute arterial pressure is below 50mm of Hg at the calf or ankle level, then the patient is to be excluded.) Subject has significant peripheral neuropathy, defined as a subject with Type I or Type II diabetes or similar systemic metabolic condition causing decreased sensation in a stocking-like or non-radicular and non-dermatomal distribution in the lower extremities. Subject has insulin-dependent diabetes mellitus. Subject is morbidly obese (defined as a body mass index >40, or weighs more than 100 lbs over ideal body weight). Subject has been diagnosed with active hepatitis, AIDS, or HIV. Subject has been diagnosed with rheumatoid arthritis or other autoimmune disease. Subject has a known allergy to titanium, polyethylene or polyester materials. Any subject that cannot have a baseline MRI taken. Subject is pregnant or interested in becoming pregnant in the next 2 years. Subject has active tuberculosis or has had tuberculosis in the past three (3) years. Subject has a history of active malignancy: A subject with a history of any invasive malignancy (except non-melanoma skin cancer), unless he/she has been treated with curative intent and there have been no signs or symptoms of the malignancy for at least two (2) years. Subject is immunologically suppressed, received steroids >1 month over the past year. Currently taking anticoagulants, other than aspirin, unless the patient can be taken off the anticoagulant for surgery. Subject has a current chemical/alcohol dependency or significant psychosocial disturbance. Subject has a life expectancy of less than three (3) years. Subject is currently involved in active spinal litigation. Subject is currently involved in another investigational study. Subject is incarcerated. Any contraindication for MRI (e.g. claustrophobia, contrast allergy).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
David H Kim, MD
Organizational Affiliation
New England Baptist Hospital
Official's Role
Study Chair
Facility Information:
Facility Name
UC San Diego Health System
City
San Diego
State/Province
California
ZIP/Postal Code
92037
Country
United States
Facility Name
Baptist - Lyerly Neurosurgery
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32207
Country
United States
Facility Name
North Shore University Health System
City
Evanston
State/Province
Illinois
ZIP/Postal Code
60201
Country
United States
Facility Name
Indiana Spine Group
City
Carmel
State/Province
Indiana
ZIP/Postal Code
46032
Country
United States
Facility Name
Orthopaedic Institute of Western Kentucky
City
Paducah
State/Province
Kentucky
ZIP/Postal Code
42001
Country
United States
Facility Name
Louisiana Spine Institute
City
Shreveport
State/Province
Louisiana
ZIP/Postal Code
71101-4643
Country
United States
Facility Name
Salt Lake Orthopaedic Clinic
City
Salt Lake City
State/Province
Utah
ZIP/Postal Code
84124
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
31464935
Citation
Strenge KB, DiPaola CP, Miller LE, Hill CP, Whitmore RG. Multicenter study of lumbar discectomy with Barricaid annular closure device for prevention of lumbar disc reherniation in US patients: A historically controlled post-market study protocol. Medicine (Baltimore). 2019 Aug;98(35):e16953. doi: 10.1097/MD.0000000000016953.
Results Reference
derived

Learn more about this trial

Study of Lumbar Discectomy With Annular Closure

We'll reach out to this number within 24 hrs